First-line nivolumab promising in advanced NSCLC

Phase I results published in the Journal of Clinical Oncology suggest that nivolumab, either given alone or alongside platinum-based doublet chemotherapy, could have a role in the first-line treatment of advanced non-small-cell lung cancer.

Source: MedWire News - July 4, 2016 Category: Consumer Health News Tags: Non-small-cell lung cancer Source Type: news